Industry Veteran Named CEO of Vigilant Biosciences
New “rinse and spit” screen for oral cancer could reduce disfigurement and save lives. Vigilant Biosciences, Inc., recently announced the appointment of David Barshis as Chief Executive Officer.
Articles by admin
This Week In Diagnostics
Peter Winter, consultant to the biotechnology industry brings us financings and business developments in the global diagnostics business in his column “This Week In Diagnostics“. Peter has over 30 years experience as a scientist, science journalist, and publisher.
Compassionate Use of Pluristem’s PLX Cells Saves the Life of a Child after Bone Marrow Transplantation Failure
IM Injections of PLX Cells Causing a Dramatic Recovery of Blood Forming Cells.
This Week in Diagnostics
Peter Winter, consultant to the biotechnology industry brings us financings and business developments in the global diagnostics business in his column “This Week In Diagnostics“. Peter has over 30 years experience as a scientist, science journalist, and publisher.
NanoViricides Announces Issuance of a Fundamental Patent in the USA
NanoViricides, Inc. (OTC BB: NNVC) announced that a fundamental patent, on which the nanoviricides® technology is based, is due to be issued in the USA on May 8, 2012. The issuance notification was received from the US Patents and Trademarks Office last week.
This Week In Diagnostics
Peter Winter, consultant to the biotechnology industry brings us financings and business developments in the global diagnostics business in his column “This Week In Diagnostics“. Peter has over 30 years experience as a scientist, science journalist, and publisher.
OneMedRadio Discusses Gene Therapy and Diagnostics with Dr. Andrew Senyei
OneMedRadio interviewed, Andrew Senyei, an MD with an interest in individualized DNA sequencing and gene therapy for heart disease.
Biovest CEO and Sr. Vice President Discuss Global Marketing of BiovaxID
Biovest International, Inc. (OTCQB: BVTI) announced that Biovest is seeking marketing approval in Canada for BiovaxID®, its personalized cancer vaccine for the treatment of follicular non-Hodgkin’s lymphoma.
NeuroMetrix Files 510(k) for SENSUS(TM) Pain Therapy Device
NeuroMetrix, Inc. (Nasdaq: NURO), a medical device company focused on the diagnosis and treatment of the neurological complications of diabetes has filed a 510(k), with the FDA for its SENSUS Pain Therapy device.
Brain Resource: Revolutionizing a Common Perception of Depression
Their concept is simple: positive thoughts reduce depression. Train your brain to increase positive thoughts.